The Archive
Every edition of The Vital Record, preserved at a permanent, dated address. Nothing is ever silently rewritten.
Tuesday, 2 June 2026 Vol. 1 · No. 1 · 10 stories
- Biotech Business Daraxonrasib roughly doubles survival over chemotherapy in previously treated metastatic pancreatic cancer
- Opinion What a doubling of survival in pancreatic cancer does — and doesn't — change
- Public Health WHO declares Bundibugyo Ebola a global emergency as DRC-Uganda outbreak tops 130 confirmed cases
- Research Adjuvant nivolumab does not extend disease-free survival after lung cancer surgery in NCI trial
- FDA & Regulatory FDA approves baxdrostat, the first aldosterone synthase inhibitor for hard-to-control hypertension
- Clinical Trials AstraZeneca opens VECTRA-01, a Phase 3 test of alpha-emitter AZD2265 in prostate cancer after beta-emitter therapy
- FDA & Regulatory FDA grants accelerated approval to bulevirtide, the first US therapy for chronic hepatitis delta
- Research In PD-L1-positive gastric cancer, adding serplulimab to surgery chemotherapy delays relapse — but survival data are immature
- FDA & Regulatory EMA committee recommends approving Boehringer's nerandomilast for two pulmonary fibrosis indications
- Biotech Business Celcuity reports a PIK3CA-mutant breast cancer win for gedatolisib over alpelisib, with the actual numbers due at ASCO on June 2